Regulatory Affairs – Page 4

Post-approval change misclassified during post-approval maintenance – CAPA and strategy reset

Identifying the symptoms of a misclassified post-approval change begins with diligent monitoring and reporting within manufacturing and quality control environments. Here are some common signals that may indicate a misclassification…

Post-approval change misclassified during lifecycle management – how to avoid repeat deficiencies

Identifying misclassified PACs often begins with observation of deviation signals in the manufacturing or quality control environments. Symptoms may include:Click to read the full article.

Deficiency response rejected by agency during lifecycle management – how to avoid repeat deficiencies

Detecting early warning signals that indicate potential deficiencies during the lifecycle of a drug product is pivotal for maintaining compliance. Common symptoms or signals that may suggest an impending rejection…

CMC section queries unresolved during variation planning – CAPA and strategy reset

Identifying symptoms or signals that indicate unresolved CMC section queries is the first step in initiating a thorough investigation. Such signals can manifest in various forms, and recognizing these early…

Submission delayed due to data gaps during agency query response – documentation gaps inspectors question

Prior to any investigation, it's essential to recognize the symptoms or signals that suggest documentation gaps may exist. These symptoms can manifest in several ways:Click to read the full article.

Post-approval change misclassified during variation planning – how to avoid repeat deficiencies

Identifying misclassified post-approval changes begins with recognizing warning signals on the manufacturing floor or in the laboratory. Some common symptoms may include:Click to read the full article.

Post-approval change misclassified during lifecycle management – FDA/EMA expectations and how to respond

The first step in addressing a post-approval change misclassification is identifying the symptoms or signals indicating a potential issue. Common symptoms may include:Click to read the full article.

CMC section queries unresolved during lifecycle management – documentation gaps inspectors question

Identifying the symptoms or signals that indicate unresolved CMC section queries is the first step in your investigation. Common signs include:Click to read the full article.

Deficiency response rejected by agency during agency query response – FDA/EMA expectations and how to respond

The initial indicators of a deficiency response rejection are critical for initiating an investigation. Symptoms can arise from various operational stages, from manufacturing to quality control. You need to look…

Submission delayed due to data gaps during variation planning – documentation gaps inspectors question

Identifying symptoms or signals that indicate potential data gaps in variation planning is the first step in addressing compliance issues. Common indicators include:Click to read the full article.

Post-approval change misclassified during agency query response – FDA/EMA expectations and how to respond

Identifying the symptoms of misclassified post-approval changes is critical for timely and effective remediation. Symptoms may manifest as discrepancies in documentation, unexpected deviations during manufacturing, or inconsistencies in product quality.…

Inconsistent global strategy during lifecycle management – documentation gaps inspectors question

Understanding the symptoms that may indicate an inconsistent global strategy during lifecycle management is essential for early intervention. Some common signs include:Click to read the full article.